IPAC Pharmaceuticals

Investing in the exploding biotech market in Asia


(

Private Fundraise

This company may be interested in raising funds from accredited investors. You must Request Access to see more information about this company.

Request Access 9

WE SEE FURTHER
IPAC Pharmaceuticals:
Fast Facts

IPAC Pharmaceuticals is an innovative biotechnology company developing a portfolio of best-in-class and first-in-class ophthalmology assets in Asia for global markets. We have a disruptive platform in development for ocular pain and are in discussions to acquire clinical stage assets for glaucoma and acute macular degeneration – there are no cures for these diseases

WE SEE FURTHER
Access to Fast 
Growing Asian Markets

Western biotech companies are creating novel drugs, but do not trust or have access to reliably get their solutions through the Asian regulatory approval process and into the market.

This makes it difficult for these companies to take advantage of the growing ophthalmology market. The opportunity in China is particularly exciting, as China is behind the developed world in ocular care and the government is making large investments to address this issue.

IPAC Pharmaceuticals obtain rights to these assets for Asia and receives tremendous upside with commercial rights to Asia.

WE SEE FURTHER
Exploding Biotech Market

The Asian markets have the highest valuations for biotech companies, particularly the Hong Kong Stock Exchange. Multiple biotech companies list with valuations in excess of $1 billion.  These companies in China have tremendous need for novel products to bring to the market to further drive value.  IPAC has the ability to collaborate with these companies on disruptive technologies from Western biotechs.  We can also help Western companies "pull forward" revenue in a region that otherwise would not be commercial for many years. Additionally, development in Asia results in data that can be leveraged for drug approval in countries around the world.

The accelerator development program we run at IACTA allows us to capitalize on this exploding market. 

WE SEE FURTHER
How It Works

We accelerate development by leveraging Asia for revenue and value globally.

WE SEE FURTHER
Traction & Accomplishments 



WE SEE FURTHER
Meet The Team 

Damon Burrows, Chief Executive Officer

  • 20+ years of experience in the life sciences and healthcare industries
  • Previously with Allergan and Roche

Eric Carter, Chief Medical Officer

  • 25+ years of experience in global pharmaceutical and device research
  • Previously with Allergan, King Pharmaceuticals and GSK

Orest Olejnik, Chief Science Officer

  • 35+ years of product development experience within the life sciences industry
  • Previously with Allergan, Johnson & Johnson, CooperVision and Fisons
  • 30+ product approvals in the US and hundreds globally

Steve Johnson, Chief Operating Officer

  • 30+ years of demonstrated success in the biopharma and medical device industries
  • Previously with Allergan and Hoechst
  • 30+ product approvals in the US and hundreds globally

Yogesh Bahl, Chief Financial Officer

  • 25+ years in life sciences
  • Ex-Partner at Deloitte and AlixPartners

Bob Ai, Business Development and Commercial Advisor

  • 25+ years of experience in biotechnology, transactions in China, strategy and finance
  • Previously with Solebury Trout, WallachBeth Capital, and Merlin Nexus

Xiaofeng “John” Xu, Commercial Advisor

  • 20 years in the healthcare industry in North America and Asia
  • Previously with Schering, Bayer Schering, AstraZeneca, and Roche

The Business Plan area is locked. You must Request Access to this company to see more information including the Business Plan.


Request Access

N

No updates yet.




%

No backers yet.




Quick Signup TBD

You must have an account to do this!


the startups.com platform

Copyright © 2019 Startups.com. All rights reserved.

Fundable is a software as a service crowdfunding platform. Fundable is not a registered broker-dealer and does not offer investment advice or advise on the raising of capital through securities offerings. Fundable does not recommend or otherwise suggest that any investor make an investment in a particular company, or that any company offer securities to a particular investor. Fundable takes no part in the negotiation or execution of transactions for the purchase or sale of securities, and at no time has possession of funds or securities. No securities transactions are executed or negotiated on or through the Fundable platform. Fundable receives no compensation in connection with the purchase or sale of securities.